tiprankstipranks
Trending News
More News >

Biofrontera AG Reports 2024 Financial Results and Strategic Growth Plans

Story Highlights
  • Biofrontera AG achieved significant sales growth in Europe and expanded its product portfolio.
  • Despite US revenue challenges, Biofrontera remained EBITDA-positive and expects profitability in 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Biofrontera AG Reports 2024 Financial Results and Strategic Growth Plans

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Biofrontera ( (DE:B8FK) ).

Biofrontera AG reported its financial results for 2024, highlighting a significant sales growth in Europe and strategic partnerships to expand its product portfolio. Despite a decrease in US revenues and ongoing litigation expenses, the company remained EBITDA-positive in its core operations. The company anticipates continued revenue growth in Europe for 2025, with Germany as a key driver, and expects to return to profitability as litigation expenses have been provisioned.

More about Biofrontera

Biofrontera AG is an international biopharmaceutical company focused on dermatological products. The company is known for its product Ameluz®, which is used in photodynamic therapy, and has recently expanded its portfolio through partnerships with Leo Pharma GmbH and Galenica AB in key markets like Germany and the UK.

Technical Sentiment Signal: Buy

Current Market Cap: €14.95M

See more data about B8FK stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1